In mouse models of JAK2 (V617F)-MPN, JAK2 inhibitors markedly reduced splenomegaly and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival of mice. The gene discussed is JAK2; the disease is myeloproliferative disorder.